Skip to main content
S&P 5007,688.62+1.58%DOW53,356.12+3.03%NASDAQ25,736.51+1.44%BTC$80,512.00+3.73%ETH$2,425.60+6.33%GOLD$4,073.90+0.02%OIL$88.26+0.16%
Smart Investors Daily
SID Premium
MB

NASDAQ · MBAI

Check-Cap Ltd. Ordinary Share

Healthcare · Medical - Diagnostics & Research

$2.05

Up+$0.03 (+1.46%)

Updated Nov 4, 2026, 11:54 PM

SID Score

4.2/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
10.47M
P/E ratio
-0.42
Dividend yield
0.00%
52-week range
$0.95 – $10.48
Volume
144.27K
Avg. volume
3.04M

Price performance · MBAI

MBAI price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

MBAI closed at $2.05 after 21 trading sessions, down 36.73% for the selected period.

Last close
$2.05
Period change
-36.73%
Period low
$1.78
Period high
$3.39
Daily close
View OHLC price history
MBAI OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$1.67$2.05$1.611$2.05144.27K
Nov 2, 2026$1.89$1.91$1.78$1.7825.58K
Oct 30, 2026$2.04$2.04$1.83$1.8820.94K
Oct 29, 2026$2.04$2.6393$2.04$2.0925.05K
Oct 28, 2026$1.74$2.07$1.73$2.04513.69K
Oct 27, 2026$2.00$2.00$1.79$1.8013.54K
Oct 26, 2026$2.02$2.045$1.845$1.9527.07K
Oct 23, 2026$2.05$2.0877$2.04$2.0658.04K
Oct 22, 2026$2.13$2.20$2.04$2.0516.87K
Oct 21, 2026$2.328$2.50$2.20$2.2010.73K
Oct 20, 2026$2.23$2.405$2.147$2.3726.65K
Oct 19, 2026$2.60$2.62$2.21$2.25543.36K
Oct 16, 2026$3.08$3.08$2.5775$2.7524.56K
Oct 15, 2026$3.00$3.20$3.00$3.1023.92K
Oct 14, 2026$3.01$3.1113$3.00$3.0513.54K
Oct 13, 2026$3.34$3.38$3.01$3.0715.01K
Oct 12, 2026$3.22$3.42$3.22$3.3918.73K
Oct 9, 2026$3.045$3.255$3.035$3.2559.89K
Oct 8, 2026$3.15$3.225$3.00$3.0117.11K
Oct 7, 2026$3.21$3.35$3.16$3.2121.2K
Oct 6, 2026$3.27$3.27$3.1501$3.2415.56K

Latest MBAI news

The latest Smart Investors Daily articles mentioning MBAI.

Stock researchCompany · Overview

MBAI research

Overview

Company profile and research snapshot.

Company profile

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but it currently expects to market products in the United States, Europe, Israel and Japan.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
MBAI recent ratings
DateFirmRatingTarget
Sep 28, 2026Northland Capital MarketsOutperform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 22, 2026

MBody AI Grows Resort Business with Caribe Royale Orlando as New Customer

AAA Four Diamond property becomes MBody’s first multi-year commercial partner in Florida, extending the company’s physical AI business beyond casino-resortsHighlights First non-casino resort customer and first commercial account in Florida.MBody will provide Caribe Royale Orlando physical AI hardware, service & its proprietary Orchestrator™ software. LAS VEGAS and ORLANDO, Fla., Oct. 22, 2026 (GLOBE NEWSWIRE) -- MBody AI Ltd. (“MBody AI” or the “Company”) (Nasdaq: MBAI) today announced Caribe Ro

Yahoo · Oct 8, 2026

MBody AI Adds 2 Patents Pending for Its Enterprise AI Workforce Platform

Nasdaq-listed AI company MBody AI ($MBAI) files two new applications as it continues to develop and deploy Orchestrator for enterprise customers LAS VEGAS, Oct. 08, 2026 (GLOBE NEWSWIRE) -- MBody AI Ltd. ("MBody AI" or the "Company") (NASDAQ: MBAI) today announced two new patent applications as it continues to develop and deploy Orchestrator for enterprise customers, including Fortune 500 operators. The latest applications, seek protection for the platform's AI architecture and separate AI techn

Yahoo · Oct 7, 2026

MBody AI Brings Physical AI Robotics Platform to ThinkEquity and Maxim Investors

Nasdaq-listed physical AI company will show investors how its Orchestrator runs robots from multiple manufacturers for Fortune 500 hotel and casino operatorsLAS VEGAS, Oct. 07, 2026 (GLOBE NEWSWIRE) -- MBody AI Ltd. ("MBody AI" or the "Company") (NASDAQ: MBAI) today announced that Chief Executive Officer John Fowler will present the Company's physical AI OrchestratorTM platform at The ThinkEquity Conference 2026 on October 15, following one-on-one investor meetings at the Maxim Growth Summit 202

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By